Sign Up to like & get
recommendations!
0
Published in 2020 at "European Journal of Nutrition"
DOI: 10.1007/s00394-020-02271-8
Abstract: Purpose The connection between gut microbiota imbalance, inflammation and its role in the pathogenesis of metabolic syndrome (MetS) clustering factors has been increasingly recognized. However, data on the efficacy of probiotics supplementation on MetS components…
read more here.
Keywords:
placebo controlled;
treatment;
group;
elderly patients ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Neuro-Oncology"
DOI: 10.1093/neuonc/nox209
Abstract: Background This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma. Methods…
read more here.
Keywords:
newly diagnosed;
study;
diagnosed glioblastoma;
oncology ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "European Addiction Research"
DOI: 10.1159/000496194
Abstract: Opioid dependence is an increasing clinical and public health problem. Current pharmacotherapies have limited efficacy and cause serious side effects. Increasing bodies of evidences suggest the neuropeptide, oxytocin (OT), as a potential treatment for drug…
read more here.
Keywords:
randomized double;
heroin dependent;
heroin;
withdrawal ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Clinical Rehabilitation"
DOI: 10.1177/0269215518760696
Abstract: Objective: This study aimed to investigate the effect of continuous progressive resistance training on body composition, functional capacity and self-reported quality of life in end-stage renal disease patients. Design: A randomized controlled trial. Subjects: The…
read more here.
Keywords:
progressive resistance;
body composition;
training;
resistance training ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.14
Abstract: 14Background: Docetaxel (DOC) and abiraterone (ABI) both improve overall survival (OS) in men with locally advanced or metastatic hormone-sensitive prostate cancer (HSPC) but no head to head trials...
read more here.
Keywords:
comparative quality;
life patients;
abiraterone;
quality life ... See more keywords